权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nebraska Center for Molecular Target Discovery and Development

内布拉斯加州分子靶点发现和开发中心

基本信息

批准号：
10714236
负责人：
Robert E. Lewis
金额：
$ 230.25万
依托单位：
UNIVERSITY OF NEBRASKA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-03-16 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10714236
关键词：
Appointment Award Awareness Basic Science Belief Biological Biological Models Biology Biomedical Research Career Mobility Cells Centers of Research Excellence Chemicals Classification Clinical Collaborations Data Data Analyses Data Set Dedications Development Discipline Disease Evaluation Faculty Financial Support Funding Future Generations Genomics Goals Grant Health Homeostasis Human Infrastructure Institution Investments Journals Medical center Mentors Modernization Molecular Molecular Analysis Molecular Target Nebraska Organoids Phase Pre-Clinical Model Protac Reagent Research Research Personnel Research Project Grants Research Support Resource Sharing Resources System Taxes Teacher Professional Development Techniques Technology Therapeutic Time Training Universities Validation Vision analytical method bench to bedside college cost data acquisition expectation experience faculty support genetic analysis improved inhibitor insight interest member novel novel therapeutics operation preclinical development programs research and development skill acquisition small molecule success technology development therapeutic development therapeutic target transcriptomics undergraduate student

项目摘要

Project Summary: Overall The goal of the Nebraska Center for Molecular Target Discovery and Development (CMTDD) is to establish and expand physical and intellectual resources at the University of Nebraska Medical Center (UNMC) and the University of Nebraska system to catalyze the identification, validation, and development of approaches for manipulation of molecular targets implicated in clinically important diseases. We perceive an increasing expectation by journals and granting agencies for progressively sophisticated model systems and data sets. Acquisition of these systems and generation of high-content data often requires a substantial investment in time and money that taxes limited research resources. To enhance the competitiveness of CMTDD Research Project Leaders (RPLs) and other university faculty members during Phase 2, the CMTDD recently invested in the development of technologies to enhance the sophistication of investigator research while minimizing the cost of access. These technologies: single-cell and spatial transcriptomic analysis, organoid generation and manipulation, and inhibitor and proteolysis-targeting chimera (PROTAC) synthesis will be integrated into three Phase 2 CMTDD cores. These investments will enhance the research capabilities of the institution, expand the translational capacity of its faculty, facilitate the training, mentoring, and career advancement of promising new faculty, and efficiently drive discovery and development for the improvement of human health in Nebraska and the nation. Phase 2 RPLs bring a breadth of cutting-edge expertise to the CMTDD. With mentoring and ready access to CMTDD-supported cores, our RPLs will become self-supporting faculty members invaluable to the future success of UNMC. Our Phase 2 RPLs share both a passion for exploration of the basic biologic principles that underly cell homeostasis and a belief that many diseases can be effectively classified and characterized through detailed genomic, genetic, and molecular analyses that identify drivers and vulnerabilities from which will emerge unique therapeutic approaches. To realize this vision, the CMTDD will: 1) maintain an Administrative Core and mentoring program that successfully graduated all but one of its initial RPLs in the first four years of support; 2) increase research capacity through newly established state-of-the-art scientific cores for single-cell and spatial transcriptomics, organoid development, and inhibitor and PROTAC synthesis and validation; and 3) provide low- or no-cost access to these technologies and reagents as an affordable means for increasing the impact of investigator research.

项目概要：总体内布拉斯加州分子靶标发现和开发中心（CMTDD）的目标是建立和扩大内布拉斯加大学医学中心（UNMC）的物质和智力资源，内布拉斯加大学系统，以促进识别，验证和开发的方法，操纵与临床重要疾病有关的分子靶点。我们发现，期刊和授权机构对日益复杂的模型系统和数据集的期望。获取这些系统和生成高内容数据往往需要大量的时间投资和对有限的研究资源征税的资金。提高CMTDD研究项目的竞争力在第二阶段，CMTDD最近投资了开发技术，以提高调查研究的复杂性，同时最大限度地减少成本， access.这些技术：单细胞和空间转录组学分析，类器官生成和操纵，抑制剂和蛋白水解靶向嵌合体（PROTAC）的合成将被整合到三个第2阶段CMTDD核心。这些投资将提高该机构的研究能力，扩大其教师的翻译能力，促进培训，指导，和有前途的新的职业发展教师，并有效地推动发现和发展，以改善人类健康在内布拉斯加州和归国第2阶段RPL为CMTDD带来了广泛的尖端专业知识。通过指导和准备获得CMTDD支持的核心，我们的RPL将成为自我支持的教师成员，对联合国军事委员会未来的成功。我们的第二阶段RPL既有对探索基本生物学原理的热情，这是细胞内稳态的基础，并相信许多疾病可以有效地分类和表征，通过详细的基因组，遗传和分子分析，确定驱动程序和漏洞，将出现独特的治疗方法。为了实现这一愿景，CMTDD将：1）维持一个行政核心和指导计划，成功毕业的所有，但其中一个最初的RPL在第一个四年，支持; 2）通过新建立的最先进的单细胞科学核心提高研究能力和空间转录组学、类器官发育、抑制剂和PROTAC合成和验证;以及3）提供低成本或免费获得这些技术和试剂的机会，作为增加调查员研究的影响。

项目成果

期刊论文数量（13）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Ubiquitin E3 ligase FBXO21 regulates cytokine-mediated signaling pathways, but is dispensable for steady-state hematopoiesis.

泛素 E3 连接酶 FBXO21 调节细胞因子介导的信号通路，但对于稳态造血来说是可有可无的。

DOI：
10.1016/j.exphem.2022.08.002
发表时间：
2022
期刊：
Experimental hematology
影响因子：
2.6
作者：
Wittorf,KarliJ;Weber,KasidyK;Swenson,SamanthaA;Buckley,ShannonM
通讯作者：
Buckley,ShannonM

Functional requirements for a Samd14-capping protein complex in stress erythropoiesis.

DOI：
10.7554/elife.76497
发表时间：
2022-06-17
期刊：
ELIFE
影响因子：
7.7
作者：
Ray, Suhita;Chee, Linda;Zhou, Yichao;Schaefer, Meg A.;Naldrett, Michael J.;Alvarez, Sophie;Woods, Nicholas T.;Hewitt, Kyle J.
通讯作者：
Hewitt, Kyle J.

Isolation and Immunodetection of Enzymatic DNA-Protein Crosslinks by RADAR Assay.

通过 RADAR 测定法分离和免疫检测酶促 DNA-蛋白质交联。